Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy

Epilepsia

Volumn 44, Issue 7, 2003, Pages 877-885

  Gouder, Nicolette ^a   Fritschy, Jean Marc ^a   Boison, Detlev ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

A1 receptor; Adenosine; CCPA; Kainic acid; Pharmacoresistant epilepsy

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; KAINIC ACID; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG PENETRATION; DRUG SELECTIVITY; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; IMPLANT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECORDING; RECURRENT DISEASE; SEIZURE; TEMPORAL LOBE EPILEPSY;

ADENOSINE; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; EPILEPSY, TEMPORAL LOBE; HIPPOCAMPUS; INJECTIONS; KAINIC ACID; MALE; MICE; MICE, INBRED STRAINS; RECEPTORS, PURINERGIC P1; TEMPORAL LOBE;

EID: 0037478606     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.03603.x     Document Type: Article

References (46)

1. Loscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2002;23:113-8.
2. Devinsky O. Patients with refractory seizures. N Engl J Med 1999;340:1565-70.
3. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000;60:23-33.
4. Foldvary N, Bingaman WE, Wyllie E. Surgical treatment of epilepsy. Neurol Clin 2001;19:491-515.
5. Ojemann GA. Treatment of temporal lobe epilepsy. Annu Rev Med 1997;48:317-28.
6. Uthman BM. Vagus nerve stimulation for seizures. Arch Med Res 2000;31:300-3.
7. Yang XF, Rothman SM. Focal cooling rapidly terminates experimental neocortical seizures. Ann Neurol 2001;49:721-6.
8. Regis J, Bartolomei F, Rey M, et al. Gamma knife surgery for mesial temporal lobe epilepsy. J Neurosurg 2000;93(suppl 3):141-6.
9. Jallon P. The problem of intractability: the continuing need for new medical therapies in epilepsy. Epilepsia 1997;38:S37-42.
10. Bouilleret V, Loup F, Kiener T, et al. Early loss of interneurons and delayed subunit-specific changes in GABA(A)-receptor expression in a mouse model of mesial temporal lobe epilepsy. Hippocampus 2000;10:305-24.
11. Bouilleret V, Ridoux V, Depaulis A, et al. Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. Neuroscience 1999;89:717-29.
12. Riban V, Bouilleret V, Pham-Le BT, et al. Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy. Neuroscience 2002;112:101-11.
13. Suzuki F, Junier MP, Guilhem D, et al. Morphogenetic effect of kainate on adult hippocampal neurons associated with a prolonged expression of brain-derived neurotrophic factor. Neuroscience 1995;64:665-74.
14. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14.
15. Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31.
16. Dragunow M, Goddard GV, Laverty R. Is adenosine an endogenous anticonvulsant? Epilepsia 1985;26:480-7.
17. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55.
18. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 2002;14:99-108.
19. Fredholm BB, Ijzermann AP, Jacobson KA, et al. International Union of Pharmacology, XXV: nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52.
20. Palmer TM, Stiles GL. Adenosine receptors. Neuropharmacology 1995;34:683-94.
21. 2+ channels in supporting hippocampal synaptic transmission. Science 1994;264:107-11.
22. Rudolphi KA, Schubert P, Parkinson FE, et al. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol Sci 1992;13:439-45.
23. + channels in rat hippocampal pyramidal cells. J Physiol 2002;539:67-75.
24. During MJ, Spencer DD. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 1992;32:618-24.
25. Huber A, Padrun V, Déglon N, et al. Grafts of adenosine releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci USA 2001;98:7611-6.
26. Boison D, Scheurer L, Tseng JL, et al. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp Neurol 1999;160:164-74.
27. Fredholm BB. Adenosine and neuroprotection. Int Rev Neurobiol 1997;40:259-80.
28. Boison D, Huber A, Padrun V, et al. Seizure suppression by adenosine releasing cells is independent of seizure frequency. Epilepsia 2002;43:788-96.
29. Huber A, Güttinger M, Möhler H, et al. Seizure suppression by adenosine A2A receptor activation in a rat model of audiogenic brainstem epilepsy. Neurosci Lett 2002;329:289-92.
30. Faingold CL. The genetically epilepsy-prone rat. Gen Pharmacol 1988;19:331-8.
31. Knuesel I, Zuellig RA, Schaub MC, et al. Alterations in dystrophin and utrophin expression parallel the reorganization of GABAergic synapses in a mouse model of temporal lobe epilepsy. Eur J Neurosci 2001;13:1113-24.
32. 6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn Schmiedebergs Arch Phannacol 1988;337:687-9.
33. Dunwiddie TV. Adenosine and suppression of seizures. Adv Neurol 1999;79:1001-10.
34. MacGregor DG, Miller WJ, Stone TW. Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor. Br J Pharmacol 1993;110:470-6.
35. Young D, Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience 1994;58:245-61.
36. 6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain. J Pharmacol Exp Ther 1993;267:844-51.
37. De Sarro G, De Sarro A, Di Paola ED, et al. Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur J Pharmacol 1999;371:137-45.
38. 6-cyclopentyladenosine. Arzneimittelforschung 1994;44:1305-12.
39. Bortolotto ZA, Mello LEM, Turski L, et al. Effects of 2-chloroadenosine on amygdaloid and hippocampal kindled seizures. Arch lnt Pharmacodyn 1985;277:313.
40. Abdulghani AS, Attwell PJE, Bradford HF. The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures. Eur J Pharmacol 1997;326:7-14.
41. Loscher W, Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. J Pharmacol Exp Ther 1991;258:483-9.
42. Bouilleret V, Boyet S, Marescaux C, et al. Mapping of the progressive metabolic changes occurring during the development of hippocampal sclerosis in a model of mesial temporal lobe epilepsy. Brain Res 2000;852:255-62.
43. Bouilleret V, Schwaller B, Schurmans S, et al. Neurodegenerative and morphogenic changes in a mouse model of temporal lobe epilepsy do not depend on the expression of the calcium-binding proteins parvalbumin, calbindin, or calretinin. Neuroscience 2000;97:47-58.
44. + nucleoside cotransporter CNT2. J Cereb Blood Flow Metab 2001;21:929-36.
45. O'Kane RL, Martinez-Lopez I, DeJoseph MR, et al. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier: a mechanism for glutamate removal. J Biol Chem 1999;274:31891-5.
46. Pardridge WM, Yoshikawa T, Kang Y-S, et al. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Pharmacol Exp Ther 1994;268:14-8.